Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00716560

Enrollment

Registered

2008-07-16

Start date

2005-05-31

Completion date

2009-03-31

Last updated

2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Melanoma, Nausea

Brief summary

The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.

Detailed description

Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* confirmed diagnosis metastatic melanoma * 18 years and older * undergoing chemotherapy with Dartmouth regimen * medically stable to receive chemotherapy per physical and clinical laboratory tests

Exclusion criteria

* No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy * No cognitive disorder that impairs symptom assessment * No other investigational agent * Inability to swallow medications for nausea and vomiting * No gastric outlet obstruction

Design outcomes

Primary

Measure	Time frame
Determine incidence of nausea when receiving Dartmouth regimen chemotherapy for metastatic melanoma	Week of treatment

Secondary

Measure	Time frame
Assess the impact of systemic chemotherapy with Dartmouth regimen on quality of life of patients	week of treatment

Countries

United States

Outcome results